Skip to content

US · BNTC · BIOTECHNOLOGY

Benitec Biopharma Inc. (BNTC) intrinsic value and stock valuation

$7.92as of 2026-11-21 · Mkt cap 435.96M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Benitec Biopharma Inc. DCF and intrinsic value

InvestorsCraft values BNTC with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from BNTC’s statements →

Benitec Biopharma Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Hayward, CA 94545 benitec.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-37.92M
20112025
Free cash flow
-$-23.61M
20112025
Total equity
$97.3M+56.9% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$70K$70K$60K
Operating income-$-41.77M-$-22.49M-$-19.08M-$-17.85M-$-13.6M
Net income-$-37.92M-$-21.75M-$-19.56M-$-18.21M-$-13.88M
EPSd-$-1.05M-$-2.12M-$-14.07M-$-9.48M-$-13.74M
Operating cash flow-$-23.59M-$-19.4M-$-18.01M-$-15.9M-$-12.83M
Capital expenditure-$-20K-$-180K-$0.00-$-10K-$-220K
Free cash flow-$-23.61M-$-19.58M-$-18.01M-$-15.91M-$-13.05M
Total assets$99.6M$52.2M$4.46M$5.97M$21.4M
Total debt$850K$280K$560K$810K$210K
Net debt-$-96.89M-$-50.58M-$-1.92M-$-3.25M-$-19.56M
Total equity$97.3M$47.3M$200K$2.88M$20M
Cash and short-term investments$97.7M$50.9M$2.48M$4.06M$19.8M
Income statement
20252024202320222021
Revenue$0.00$0.00$70K$70K$60K
Cost of revenue$400K$340K$0.00$10K$120K
Gross profit-$-400K-$-340K$70K$60K-$-60K
Research and development expenses$18.3M$15.6M$12.8M$11.3M$7.02M
Selling, general and administrative expenses$23.4M$6.99M$6.38M$6.65M$6.51M
Other expenses$0.00-$-110K$0.00$0.00$0.00
Operating expenses$41.8M$22.5M$19.2M$17.9M$13.5M
Cost and expenses$41.8M$22.5M$19.2M$17.9M$13.7M
Interest income$0.00$900K$0.00$0.00$0.00
Interest expense-$-3.29M$0.00$30K$30K$10K
Depreciation and amortization$400K$340K$380K$390K$420K
Ebitda-$-41.37M-$-22.15M-$-18.7M-$-17.78M-$-13.45M
Operating income-$-41.77M-$-22.49M-$-19.08M-$-17.85M-$-13.6M
Total other income/expenses, net$3.85M$740K-$-480K-$-350K-$-290K
Income before tax-$-37.92M-$-21.75M-$-19.56M-$-18.21M-$-13.88M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-37.92M-$-21.75M-$-19.56M-$-18.21M-$-13.88M
Weighted average shares outstanding$36.2M$10.3M$1.39M$1.92M$1.01M
Weighted average diluted shares outstanding$36.2M$10.3M$1.39M$1.92M$1.01M
Balance sheet
20252024202320222021
Cash and short-term investments$97.7M$50.9M$2.48M$4.06M$19.8M
Net receivables$30K$230K$60K$0.00$30K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$98.5M$51.7M$3.73M$4.82M$20.6M
Property, plant and equipment, net$990K$450K$610K$990K$580K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.07M$540K$730K$1.15M$770K
Total assets$99.6M$52.2M$4.46M$5.97M$21.4M
Accounts payable$200K$1.35M$1.14M$420K$270K
Short-term debt$350K$280K$280K$250K$210K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$1.8M$4.92M$3.98M$2.53M$1.37M
Long-term debt$490K$0.00$280K$560K$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$490K$40K$280K$560K$0.00
Capital lease obligations$850K$280K$560K$810K$210K
Total liabilities$2.3M$4.96M$4.26M$3.09M$1.37M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-228.18M-$-190.26M-$-167.89M-$-148.33M-$-130.12M
Accumulated other comprehensive income (loss)-$-840K-$-890K-$-830K-$-1.25M-$-1.46M
Total equity$97.3M$47.3M$200K$2.88M$20M
Total investments$0.00$0.00$0.00$0.00$0.00
Total debt$850K$280K$560K$810K$210K
Net debt-$-96.89M-$-50.58M-$-1.92M-$-3.25M-$-19.56M
Cash flow statement
20252024202320222021
Net income-$-37.92M-$-21.75M-$-19.56M-$-18.21M-$-13.88M
Depreciation and amortization$400K$340K$380K$390K$420K
Stock-based compensation$17.4M$830K$450K$870K$630K
Change in working capital-$-2.73M$1.17M$710K$1.04M$10K
Accounts receivable$200K-$-180K-$-50K$0.00$30K
Inventory$0.00$0.00-$-1.31M-$-1.09M-$-80K
Accounts payable-$-2.38M$0.00$1.36M$1.09M$60K
Net cash provided by operating activities-$-23.59M-$-19.4M-$-18.01M-$-15.9M-$-12.83M
Investments in property, plant and equipment-$-20K-$-180K-$0.00-$-10K-$-220K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-20K-$-180K-$0.00-$-10K-$-220K
Common stock issued$70.5M$70.9M$17.9M$0.00$25.8M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$70.5M$68M$16M$0.00$22.5M
Net change in cash$46.9M$48.4M-$-1.59M-$-15.71M$9.97M
Cash at end of period$97.9M$50.9M$2.49M$4.08M$19.8M
Operating cash flow-$-23.59M-$-19.4M-$-18.01M-$-15.9M-$-12.83M
Capital expenditure-$-20K-$-180K-$0.00-$-10K-$-220K
Free cash flow-$-23.61M-$-19.58M-$-18.01M-$-15.91M-$-13.05M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Benitec Biopharma Inc.

        Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.

        CEO
        Jerel A. Banks
        Employees
        19
        Beta
        0.25

        Explore

        Frequently asked questions

        What is the intrinsic value of Benitec Biopharma Inc. (BNTC)?

        InvestorsCraft does not currently publish an intrinsic value for BNTC. How the IC value is calculated.

        Is BNTC undervalued?

        InvestorsCraft does not publish an undervaluation signal for BNTC at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.